Evidence map›Paper›PMID 39671174›Full record

Trial reportThe Journal of infectious diseases2025

HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines.

Gregory J Wilson, L W Preston Church, Colleen F Kelley, Samuel T Robinson, Yiwen Lu, Briana D Furch, Youyi Fong, Carmen A Paez, Margaret Yacovone, Thomas Jacobsen and 8 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03856996 (A Phase 1 Double-blind, Randomized, Controlled Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03856996 phase1completednot on this map

A Phase 1 Double-blind, Randomized, Controlled Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2019 to 2021Enrolled30ConditionsHIV InfectionsArmsStable CH505TF gp120, Transient CH505TF gp120, Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Gregory J WilsonDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0009-0007-2120-0393
L W Preston ChurchVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Colleen F KelleyDepartment of Medicine, Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-5611-0119
Samuel T RobinsonVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-2356-9905
Yiwen LuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Briana D FurchVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-3018-1642
Youyi FongVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-4230-6863
Carmen A PaezVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0001-8640-6623
Margaret YacovoneNational Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA.ORCID 0000-0002-6983-8560
Thomas JacobsenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Maureen MaughanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Diana MartikDuke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Jack R HeptinstallDuke Center for Human Systems Immunology, Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Durham, North Carolina, USA.
Lu ZhangDuke Center for Human Systems Immunology, Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Durham, North Carolina, USA.
David C MontefioriDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.ORCID 0000-0003-0856-6319
Georgia D TomarasDuke Center for Human Systems Immunology, Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Durham, North Carolina, USA.
James G KublinVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-2179-2436

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
National Institute of Allergy and Infectious DiseaseNational Institute of Allergy and Infectious DiseasesNIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIH HHS UM1 AI068614
6 · The paper itself

Abstract

Utilizing transiently transfected cell lines could significantly reduce manufacturing timelines for protein subunit vaccines. This trial compared safety and immunogenicity of human immunodeficiency virus (HIV) envelope CH505TF gp120 vaccines produced by upstream stable and transient transfection (each admixed with GLA-SE adjuvant, a TL4 agonist). Both vaccines were safe and well tolerated. Serum IgG binding antibody response rates 2 weeks after final injection were 92% in the stable group and 93% in the transient group (P = 1.000). Neutralization response rates against CH505.w4.3 were also equivalent (92% vs 100%, P = .291). These data support transient transfection as an available tool for accelerating HIV vaccine testing and iteration. Clinical Trials Registration. NCT03856996.

Indexed as

AIDS VaccinesHIV Envelope Protein gp120HIV InfectionsImmunogenicity, VaccineAdultAntibodies, NeutralizingCell LineFemaleHIV-1HIV AntibodiesHumansImmunoglobulin GMaleMiddle AgedTransfectionYoung AdultAIDS VaccinesAntibodies, NeutralizingHIV AntibodiesHIV Envelope Protein gp120Immunoglobulin GHIVmanufacturingproteintransfectionvaccine

Identifiers

PMID39671174
PMCPMC11998572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.